Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XURIDEN vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Emergency treatment of fluorouracil (5-FU) overdose,Emergency treatment of capecitabine overdose
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h). Clinically relevant for dosing interval (every 6 hours).
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Xuriden is deacetylated by esterases in the plasma and tissues to release uridine, which is then further metabolized via the pyrimidine salvage pathway.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal: predominantly as intact uridine (47-62%) and uracil (16-25%); fecal/biliary: minimal (<5%).
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
<5% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Vd: 0.5-0.8 L/kg, indicating distribution into total body water.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Oral: approximately 60% (range 40-80%) due to first-pass metabolism.
100% intravenous; not administered by other routes.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or dialysis.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Weight-based dosing: 60 mg/kg orally once daily. Maximum dose 6000 mg/day. Administer with food.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
No specific dose adjustment recommended. Use with caution due to age-related decline in renal function; monitor renal function periodically.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Not indicated for non-emergency use or as prophylaxis for chemotherapy.,Should be initiated as soon as possible after overdose, ideally within 96 hours.,May cause diarrhea, nausea, vomiting, and abdominal pain.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
None known.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
Take with food to minimize gastrointestinal discomfort. No specific food restrictions; avoid excessive grapefruit juice as it may affect uridine metabolism.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effects (neural tube defects, skeletal malformations) at doses 0.4 times the human dose based on body surface area. Risk cannot be ruled out. First trimester: potential for major malformations; second and third trimesters: potential for fetal growth impairment and neurodevelopmental effects.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
No data on presence in human milk, effects on breastfed infant, or milk production. Given the molecular weight of uridine triacetate (approximately 488 Da) and its metabolic conversion, excretion into breast milk is plausible. M/P ratio not determined. Use during breastfeeding only if clearly needed and consider alternatives or pump and discard.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Physiological changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce uridine triacetate exposure. No formal dosing adjustment studies; however, monitor clinical response and consider dose adjustment based on trough levels of uridine or clinical efficacy if available. No specific pregnancy-recommended dose adjustment from manufacturer.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Xuriden (uridine triacetate) is a pyrimidine analog used for hereditary orotic aciduria. Monitor for orotic acid crystalluria; ensure adequate hydration. Administer with food to reduce GI upset. Not recommended for use with fluorouracil or capecitabine due to interference.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Take exactly as prescribed, usually once daily with food.,Do not crush or chew tablets; swallow whole.,Drink plenty of fluids to prevent kidney stones.,Report any signs of allergic reaction or severe abdominal pain.,Continue treatment even if feeling well; do not stop without consulting physician.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XURIDEN vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
XURIDEN is a Metabolic Agent that works by Xuriden (uridine triacetate) is a prodrug of uridine that restores intracellular uridine nucleotide pools, which are essential for RNA and DNA synthesis, thereby reversing the toxicity of fluorouracil (5-FU) and capecitabine overdose.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XURIDEN and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XURIDEN is: 60 mg/kg orally once daily, rounded to the nearest 60 mg increment. Maximum dose: 6000 mg/day.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XURIDEN and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XURIDEN is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of uridine triacetate during organogenesis produced teratogenic effec. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.